Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2023-07, Vol.25 (7), p.2043-2047
Hauptverfasser:	Yi, Tae Won, Wong, Michelle M.Y., Neuen, Brendon L., Arnott, Clare, Poirier, Paul, Seufert, Jochen, Slee, April, Rapattoni, Wally, Ang, Fernando G., Wheeler, David C., Mahaffey, Kenneth W., Perkovic, Vlado, Levin, Adeera
Format:	Artikel
Sprache:	eng
Schlagworte:	Antidiabetics canagliflozin Canagliflozin - therapeutic use cardiovascular disease Cardiovascular Diseases - complications Cardiovascular Diseases - drug therapy Cardiovascular Diseases - prevention & control Cardiovascular System Diabetes Diabetes Mellitus, Type 2 - chemically induced Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Humans Kidney Kidney diseases Peripheral Arterial Disease - complications Peripheral Arterial Disease - drug therapy Renal Insufficiency, Chronic - chemically induced Renal Insufficiency, Chronic - complications Renal Insufficiency, Chronic - drug therapy SGLT2 inhibitor type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!